Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round brings $21mm to Kleo

Executive Summary

Kleo Pharmaceuticals Inc. (immuno-oncology) raised $21mm through an oversubscribed Series B round led by PeptiDream (development partner under a 2017 deal) and including Biohaven Pharmaceuticals. The company is developing cancer therapies based on its Antibody Recruiting Molecules (ARM) technology, and will use the Series B funds to advance its first candidates into human studies.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies